11 results
Thumbnail

D1.372 - Potential blood biomarkers of disease activity in patients with chronic spontaneous urticaria

Thumbnail

D1.375 - Ciclosporin for omalizumab-refractory CSU in a Paediatric population in Cork University Hospital: a case series

Thumbnail

D1.376 - Emerging inmunomodulatory agents for atopic dermatitis

Thumbnail

D1.377 - Berotralstat effectively controls a type 2 Hereditary Angioedema patient, refractory to other long-term prophylaxis treatments – Case report

Thumbnail

D1.378 - Evaluating the efficacy of dupilumab treatment for atopic dermatitis across geographic areas: A systematic review and meta-regression analysis

Thumbnail

D1.379 - AllergoOncology: Generation of Equinized Anti-PD-L1 mAbs with Specific Equine Constant Regions by MOE-PCR Ligation-Independent Cloning (LIC)

Thumbnail

D1.380 - Quicker EASI 75 or greater decline of DLQI - is it significant? Comparison of dupilumab treatment among children and adults in two centres in Cracow

Thumbnail

D1.383 - Nonimmediate hypersensitivity reaction to Lanadelumab in a patient with Hereditary Angioedema: a case report

Thumbnail

D1.384 - Long-term Prophylaxis with Lanadelumab in Hereditary and Acquired Angioedema: A Single-Center Retrospective-Prospective “Real-Life” Analysis

Thumbnail

D1.385 - Dupilumab Treatment Effects on Atopic Manifestations in Patients with Inborn Errors of Immunity

Thumbnail

D1.386 - Impact of dupilumab on allergen specific immunoglobulin E production